Embryo QUAlity in Ovarian Stimulation With hMG.

ConditionInfertility
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
Age38-41
SponsorFundacion Dexeus

About this trial

Ovarian stimulation (OS) is a key component of IVF, aimed at increasing oocyte yield and improving embryo development potential. While early protocols relied solely on FSH, newer approaches incorporate hMG and LH-based stimulation, allowing more individualized treatments for specific patient populations. Evidence suggests that hMG and recombinant FSH (rFSH) have comparable effectiveness in stimulation outcomes, and current guidelines support the use of both. However, the impact of different gonadotropins on embryo quality remains unclear, with mixed findings across protocols. Given the increasing use of combined rFSH and hMG and the limited data in PPOS protocols, this study proposes a randomized controlled trial to compare embryo quality between two different rFSH-hMG dosing strategies.

Eligibility criteria

Qualifiers

Undergoing preimplantation genetic screening cycles

AMH 0.5 - 3.5 ng/ml or AFC 5-20 (results of up to one year will be valid)

BMI 18.5 - 30 Kg/m2

Normal karyotypes in both partners

Disqualifiers

Previous poor ovarian response (≤3 oocytes with a conventional stimulation protocol), according to Bologna criteria

Severe male factor requiring TESE (testicular sperm extraction)

Administration of any other drug potentially interfering with the treatment

Contraindication for hormonal treatment

Trial design

Treatments tested in this trial

  • 10 mcg of follitropin-delta + 150 of hMG
  • 5 mcg of follitropin-delta + 225 of hMG

Treatment groups

240 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Fundacion Dexeus

Lead sponsor

Ferring Pharmaceuticals

Collaborator